A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
Completed · Phase 2 · Has a placebo group
Conditions studied: C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
In brief
The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant proteinuria attributable to C3G.
Key facts
- Study ID
- NCT03369236
- Run by
- Alexion Pharmaceuticals, Inc.
- People needed
- 13
- Starts
- 2018-06-12
- Expected to finish
- 2020-12-18
- Last updated by the study team
- 2022-10-14
Who can join
Age: 17 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Study Site — Aurora, Colorado, United States
- Clinical Study Site — Lawrenceville, Georgia, United States
- Clinical Study Site — Iowa City, Iowa, United States
- Clinical Study Site — Baltimore, Maryland, United States
- Clinical Study Site — New York, New York, United States
- Clinical Study Site — New York, New York, United States
- Clinical Study Site — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.